Business
Analysts Bullish on Ardelyx Ahead of Q4 Earnings, Citing Blockbuster Potential for Key Drug
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.